Page 12 - Mike Sinclair News Today

(0) Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million. The project will advance the development of novel injectable glycopolymers to support better ABO-incompatible (ABOi) transplantation ...

GeNeuro: Financial Information for the First Quarter 2021 Net cash position of €4.8 million Debt free Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), today reported on its 2021 first quarter cash position. 2021 First-quarter financial information At March 31, 2021, GeNeuro had €4.8 million in cash. The available cash resources provid...

DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN Nuvothera acquires option to licence rights to develop and commercialise DS Biopharmas EPADILIN in the US DS Biopharma becomes an investor in Nuvothera and takes a Board seat DS Biopharma Limited, a developer of bioactive lipid based pharmaceuticals and Nuvothera Inc., a provider of dermatological commercial solutions announced today that the companies have entered into an option and license agreement. Under the terms of...

Versantis Announces Positive Phase 1b Results for VS-01 in Patients with Decompensated Cirrhosis Promising data supports advancing VS-01 into Phase 2a POC study in Acute on Chronic Liver Failure Versantis, a clinical-stage company developing novel therapies for orphan liver and pediatric diseases, today announced positive results from a Phase 1b clinical trial of VS-01 in decompensated liver cirrhosis. VS-01 was found to be safe and well tolerated in this first-in-human, single ascending and mu...

(1) PRS stratifies disease risk and brings precision medicine into clinical routine Allelica, a leading genomics software company specialising in developing polygenic risk scores (PRSs) for common diseases, today announced that the company has raised $1.75 million in a seed financing round led by Valor Ventures, Sternberg Health, Pi Campus, as well as strategic business angels also participated in the round. As part of the transaction, Valor Ventures General Partner Gary Peat has joined the All...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Reports Full Year 2020 Financial Results and Provides Corporate Update Addex TherapeuticsMarch 11, 2021 GMT Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M) Balance sheet further strengthened by $11.5M fundraising on January 11, 2021 Three clinical studies in neurology programs expected to start during H1 2021 Clinical stage neurology programs aimed at large underse...

About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addexs allosteric modu...

SUVs have been named crowned Car of the Year by two different sets of motoring experts. Carsales has awarded its prestigious prize to the Kia Sorento while Wheels has given its annual prize to the Mazda CX-30. Last year, for the first time ever, the majority of cars sold in Australia were an SUV with higher ground clearance. The category includes both front-wheel drive and all-wheel drive variants with virtually every major car manufacturer - from the budget to the super luxury - offering an SU...

John Bowmans Top Threes Long-time Montreal Alouettes defensive end John Bowman sat down with RDS’s Éric Leblanc to discuss some memorable moments from his time in Montreal. TSN.ca Staff John Bowman , Getty Images Long-time Montreal Alouettes defensive end John Bowman sat down with RDS’s Éric Leblanc (@eleblancRDS) to discuss some memorable moments from his time in Montreal. Top three teammates “This is hard because I’ve been around 14 years ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder Addex TherapeuticsFebruary 16, 2021 GMT Review from Linköping University Published in Alcohol and Alcoholism Journal Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developm...